BiotechTube

E6742

Phase 1/2Completed
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lupus Erythematosus, Systemic

Conditions

Lupus Erythematosus, Systemic

Trial Timeline

Apr 14, 2022 → Sep 4, 2023

NCT ID
NCT05278663

About E6742

E6742 is a phase 1/2 stage product being developed by Eisai for Lupus Erythematosus, Systemic. The current trial status is completed. This product is registered under clinical trial identifier NCT05278663. Target conditions include Lupus Erythematosus, Systemic.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05278663Phase 1/2Completed

Competing Products

20 competing products in Lupus Erythematosus, Systemic

See all competitors
ProductCompanyStageHype Score
Tabalumab Auto-Injector + Tabalumab Prefilled SyringeEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 2
52
DS-7011a + PlaceboDaiichi SankyoPhase 1
33
DS-7011a + PlaceboDaiichi SankyoPhase 1/2
41
tacrolimusAstellas PharmaPhase 3
77
TacrolimusAstellas PharmaPre-clinical
23
tacrolimus capsule + tacrolimus placebo + leflunomide tablet + leflunomide placebo + prednisoneAstellas PharmaPhase 3
77
tacrolimusAstellas PharmaApproved
85
Tacrolimus capsules + Cyclophosphamide injections + PrednisoneAstellas PharmaPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of CareEli LillyPhase 3
77
LY3361237 + PlaceboEli LillyPhase 2
52
LY2127399 + PlaceboEli LillyPhase 3
77
LY3361237 + PlaceboEli LillyPhase 1
33
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeksEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
LY3471851 + PlaceboEli LillyPhase 1
33
LY3471851 + PlaceboEli LillyPhase 2
52
Itolizumab [Bmab 600]BioconPhase 1
33

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85